Evaluates drug delivery and fluorescence monitoring in vascular calcification, suggesting potential therapeutic benefits.
A multifunctional alginate-based platform ( 1-Alg-2@DSS ) was developed to integrate therapeutic drug delivery with fluorescence-based safety monitoring. A bioactive microbial-derived modifier and a naphthalimide fluorophore were covalently grafted onto an alginate backbone to construct a stable carrier for Danshensu (DSS) loading. The obtained composite displayed favorable physicochemical stability, mesoporosity, and environment-sensitive fluorescence properties. In a β-glycerophosphate-induced vascular smooth muscle cell (VSMC) calcification model, DSS-loaded 1-Alg-2 exhibited good biocompatibility and effectively attenuated senescence and osteogenic phenotypic switching. Relative to free DSS, it more strongly reduced the expression of osteogenic and senescence-related markers, including Runt-related transcription factor 2 (Runx2), alkaline phosphatase (ALP) p21, interleukin-6 (IL-6), and restored sirtuin 1 (SIRT1) expression. In addition, the naphthalimide-functionalized alginate framework achieved highly selective fluorescence sensing of nitrofurazone (NFZ), with a Stern–Volmer quenching constant of 9.87 × 10 5 M⁻ 1 and a response time of 1 min, together with excellent reversibility and anti-interference capability. These results demonstrate a versatile alginate-based platform that combines vascular protective therapy with fluorescence monitoring of harmful antibiotic residues.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: